Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming
investor conferences in May. The conferences will be webcast live and
the webcasts will be available in the Investor Relations section of the
Company's website at www.celgene.com.
Celgene management will provide an overview of the Company.
Thursday, May 9, 2013 Celgene will present at Baird's 2013 Growth Stock
Conference at 1:20 p.m. ET.
Thursday, May 16, 2013 Celgene will present at the 2013 Bank of America
Merrill Lynch Global Healthcare Conference at 12:20 p.m. ET.
Wednesday, May 22, 2013 Celgene will present at the 2013 UBS Global
Healthcare Conference at 11:30 a.m. ET.
Thursday, May 30, 2013 Celgene will present at Sanford C. Bernstein's
29th Annual Strategic Decisions Conference at 9:00 a.m. ET.
Additionally, Celgene plans to host an Analyst and Institutional
Investor Day on May 6. The presentation will be webcast beginning at 1
p.m. ET and is expected to conclude at 5 p.m.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of novel therapies for the
treatment of cancer and inflammatory diseases through gene and protein
regulation. For more information, please visit the company's Web site at www.celgene.com.
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
Jacqualyn A. Fouse, Ph.D., 908-673-9956
Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969